推荐产品
制造商/商品名称
EDQM
药品控制
regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)
应用
pharmaceutical (small molecule)
SMILES字符串
Cl[H].CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4CC7CC7)c56
InChI
1S/C29H41NO4.ClH/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28;/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3;1H/t20-,21-,24-,26+,27-,28+,29-;/m1./s1
InChI key
UAIXRPCCYXNJMQ-RZIPZOSSSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
生化/生理作用
Agonist at ORL1 receptors; antagonist or partial agonist at μ, κ, and δ opioid receptors.
Full agonist at ORL1 receptors, antagonist or partial agonist at μ, κ, and δ opioid receptors.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral - Repr. 2
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Xiaofan Li et al.
Expert opinion on pharmacotherapy, 15(15), 2263-2275 (2014-08-30)
Buprenorphine follows the success of methadone as another milestone in the history of treatment for opioid addiction. Buprenorphine can be used in an office-based setting where it is clearly effective, highly accepted by patients and has a favorable safety profile
Jason R Healy et al.
American journal of veterinary research, 75(7), 619-625 (2014-06-25)
To evaluate analgesic effects of an improved sustained-release buprenorphine (BUP-SR) formulation administered to mice. 36 male Swiss-Webster mice. Mice were assigned to each of 3 treatment groups (n = 12 mice/group). Treatments were administered SC (vehicle [control treatment], 1.5 mg
[It is both permitted and forbidden to drive after taking drugs].
Clas Sjöberg
Lakartidningen, 111(18-19), 810-811 (2014-05-27)
A Z X Zhu et al.
Clinical pharmacology and therapeutics, 96(2), 256-265 (2014-04-16)
Associations between CHRNA5-A3-B4 variants and smoking behaviors exist; however, the association with smoking abstinence is less understood, particularly that among African Americans. In 1,295 African Americans enrolled in two clinical trials, we investigated the association between CHRNA5-A3-B4 and smoking abstinence.
David A Fiellin et al.
JAMA internal medicine, 174(12), 1947-1954 (2014-10-21)
Prescription opioid dependence is increasing and creates a significant public health burden, but primary care physicians lack evidence-based guidelines to decide between tapering doses followed by discontinuation of buprenorphine hydrochloride and naloxone hydrochloride therapy (hereinafter referred to as buprenorphine therapy)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门